These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 33368954)

  • 1. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis.
    Panunzi S; Maltese S; Verrastro O; Labbate L; De Gaetano A; Pompili M; Capristo E; Bornstein SR; Mingrone G
    Diabetes Obes Metab; 2021 Apr; 23(4):980-990. PubMed ID: 33368954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies.
    Pedersen JS; Rygg MO; Serizawa RR; Kristiansen VB; Albrechtsen NJW; Gluud LL; Madsbad S; Bendtsen F
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
    Lassailly G; Caiazzo R; Buob D; Pigeyre M; Verkindt H; Labreuche J; Raverdy V; Leteurtre E; Dharancy S; Louvet A; Romon M; Duhamel A; Pattou F; Mathurin P
    Gastroenterology; 2015 Aug; 149(2):379-88; quiz e15-6. PubMed ID: 25917783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.
    Ng CH; Muthiah MD; Xiao J; Chin YH; Lim G; Lim WH; Tay P; Tan DJH; Yong JN; Pan XH; Koh JWH; Chew N; Syn N; Tan E; Huang DQ; Siddiqui MS; Loomba R; Sanyal AJ; Noureddin M
    Aliment Pharmacol Ther; 2022 May; 55(9):1076-1087. PubMed ID: 35285529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease.
    Cherla DV; Rodriguez NA; Vangoitsenhoven R; Singh T; Mehta N; McCullough AJ; Brethauer SA; Schauer PR; Aminian A
    Surg Endosc; 2020 May; 34(5):2266-2272. PubMed ID: 31359195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study.
    Froylich D; Corcelles R; Daigle C; Boules M; Brethauer S; Schauer P
    Surg Obes Relat Dis; 2016 Jan; 12(1):127-31. PubMed ID: 26077701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
    Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.
    Majzoub AM; Nayfeh T; Barnard A; Munaganuru N; Dave S; Singh S; Murad MH; Loomba R
    Aliment Pharmacol Ther; 2021 Oct; 54(7):880-889. PubMed ID: 34435378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of NASH with Gastric Bypass.
    Jirapinyo P; Thompson CC
    Curr Gastroenterol Rep; 2018 Sep; 20(10):49. PubMed ID: 30244334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Secondary Analysis of a Randomized Clinical Trial.
    Kalinowski P; Paluszkiewicz R; Ziarkiewicz-Wróblewska B; Wróblewski T; Remiszewski P; Grodzicki M; Krawczyk M
    Ann Surg; 2017 Nov; 266(5):738-745. PubMed ID: 28767558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A; Akhter A
    Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.
    Lassailly G; Caiazzo R; Ntandja-Wandji LC; Gnemmi V; Baud G; Verkindt H; Ningarhari M; Louvet A; Leteurtre E; Raverdy V; Dharancy S; Pattou F; Mathurin P
    Gastroenterology; 2020 Oct; 159(4):1290-1301.e5. PubMed ID: 32553765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis.
    Sharma BC; Kumar A; Garg V; Reddy RS; Sakhuja P; Sarin SK
    J Clin Exp Hepatol; 2012 Dec; 2(4):333-7. PubMed ID: 25755455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis.
    Verbeek J; Lannoo M; Pirinen E; Ryu D; Spincemaille P; Vander Elst I; Windmolders P; Thevissen K; Cammue BP; van Pelt J; Fransis S; Van Eyken P; Ceuterick-De Groote C; Van Veldhoven PP; Bedossa P; Nevens F; Auwerx J; Cassiman D
    Gut; 2015 Apr; 64(4):673-83. PubMed ID: 24917551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to pioglitazone in non-alcoholic fatty liver disease patients with
    Wang Z; Du H; Zhao Y; Ren Y; Ma C; Chen H; Li M; Tian J; Xue C; Long G; Xu M; Jiang Y
    Front Endocrinol (Lausanne); 2023; 14():1111430. PubMed ID: 37065735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
    Singh S; Khera R; Allen AM; Murad MH; Loomba R
    Hepatology; 2015 Nov; 62(5):1417-32. PubMed ID: 26189925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.